# Novartis vs Thermo Fisher Scientific: stocks compared

URL: https://funkfolio.com/compare/nvs-vs-tmo

> Novartis ($300.5B, P/E 30.4) and Thermo Fisher Scientific ($254.5B, P/E 36.2) compared: size, valuation, margins, debt, cash and price change.

---

## Novartis vs Thermo Fisher Scientific

Novartis (NVS), health care, and Thermo Fisher Scientific (TMO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novartis is worth $300.5B on the stock market and Thermo Fisher Scientific $254.5B: Novartis is valued at 18% more. Novartis trades at 30.4 times earnings and Thermo Fisher Scientific at 36.2; operating margins in their latest fiscal years were 32.4% and 17.4%. Over the past year Novartis's share price has moved +25.1% and Thermo Fisher Scientific's +20.0%.

### Key facts

- **Novartis market value:** $300.5B
- **Thermo Fisher Scientific market value:** $254.5B
- **Novartis P/E:** 30.4
- **Thermo Fisher Scientific P/E:** 36.2
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Thermo Fisher Scientific revenue:** $44.6B FY to 2025-12-31
- **Superinvestors holding both:** 6

Market values as of 18 Nov 2026, 01:42 UTC.

Novartis vs Thermo Fisher Scientific: every measure side by side

| Measure | Novartis | Thermo Fisher Scientific |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | Switzerland | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $300.5B higher | $254.5B lower |
| Revenue | $54.5B higher | $44.6B lower |
| Earnings | $14B higher | $6.7B lower |
| Employees | 75,267 lower | 125,000 higher |
| Total assets | $110.9B higher | $110.3B lower |
| Valuation |  |  |
| P/E | 30.4 lower | 36.2 higher |
| P/S | 5.5 lower | 5.7 higher |
| P/B | — | 4.6 |
| Dividend yield | — | 0.27% |
| Profitability |  |  |
| Operating margin | 32.4% higher | 17.4% lower |
| Balance sheet |  |  |
| Net assets | $46.1B lower | $53.4B higher |
| Total liabilities | $64.4B higher | $56.8B lower |
| Total debt | $28.7B lower | $39.4B higher |
| Cash on hand | $11.4B higher | $9.9B lower |
| Price change |  |  |
| Today | -0.67% lower | -0.66% higher |
| 1 year | +25.1% higher | +20.0% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Novartis 121.8, Thermo Fisher Scientific 121.9.

- Novartis (NVS)
- Thermo Fisher Scientific (TMO)

Novartis and Thermo Fisher Scientific share prices over one year, rebased to 100: Novartis ends at 121.8, Thermo Fisher Scientific at 121.9.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | NVS | TMO |
| --- | --- | --- |
| Nov 28, 2025 | 99.1 | 104.2 |
| Dec 31, 2025 | 104.8 | 102.2 |
| Jan 30, 2026 | 113.0 | 102.0 |
| Feb 27, 2026 | 128.2 | 91.9 |
| Mar 31, 2026 | 116.1 | 86.7 |
| Apr 30, 2026 | 112.4 | 84.4 |
| May 29, 2026 | 114.2 | 86.8 |
| Jun 30, 2026 | 119.1 | 88.4 |
| Jul 31, 2026 | 118.7 | 101.3 |
| Aug 31, 2026 | 115.6 | 108.8 |
| Sep 30, 2026 | 108.4 | 119.0 |
| Oct 30, 2026 | 122.2 | 122.9 |
| Nov 16, 2026 | 121.8 | 121.9 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (6)

- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.7% / 0.6%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.6% / 0.8%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.3% / 6.3%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.2% / 1.6%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1% / 4.3%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.1% / 1.1%

#### Novartis only (7)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.8%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.4%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.3%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%

#### Thermo Fisher Scientific only (18)

- [Nick Train](https://funkfolio.com/gurus/nick-train) 12.4%
- [Wallace Weitz](https://funkfolio.com/gurus/wallace-weitz) 4.9%
- [Andreas Halvorsen](https://funkfolio.com/gurus/andreas-halvorsen) 2.8%
- [Harry Burn](https://funkfolio.com/gurus/harry-burn) 2.7%
- [Temasek](https://funkfolio.com/gurus/temasek) 2.2%
- [Doug Silverman](https://funkfolio.com/gurus/doug-silverman) 2.0%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 2.0%
- [Diamond Hill team](https://funkfolio.com/gurus/diamond-hill) 1.6%
- [John Armitage](https://funkfolio.com/gurus/john-armitage) 1.4%
- [Daniel Sundheim](https://funkfolio.com/gurus/daniel-sundheim) 0.7%
- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 0.4%
- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.4%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.2%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Novartis / Thermo Fisher Scientific). [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors) · [Who owns TMO](https://funkfolio.com/stock/TMO/superinvestors)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Thermo Fisher Scientific

- [Thermo Fisher Scientific (TMO) stock page](https://funkfolio.com/stock/TMO)
- [Thermo Fisher Scientific market cap](https://funkfolio.com/stock/TMO/market-cap)
- [Thermo Fisher Scientific revenue](https://funkfolio.com/stock/TMO/revenue)
- [Thermo Fisher Scientific P/E ratio](https://funkfolio.com/stock/TMO/pe-ratio)
- [Thermo Fisher Scientific operating margin](https://funkfolio.com/stock/TMO/operating-margin)
- [Thermo Fisher Scientific total debt](https://funkfolio.com/stock/TMO/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Novartis against its closest peers

- [Novartis vs AstraZeneca](https://funkfolio.com/compare/azn-vs-nvs)
- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Merck & Co](https://funkfolio.com/compare/mrk-vs-nvs)

#### Thermo Fisher Scientific against its closest peers

- [Thermo Fisher Scientific vs Amgen](https://funkfolio.com/compare/amgn-vs-tmo)
- [Thermo Fisher Scientific vs AstraZeneca](https://funkfolio.com/compare/azn-vs-tmo)
- [Thermo Fisher Scientific vs Gilead Sciences](https://funkfolio.com/compare/gild-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Novartis or Thermo Fisher Scientific?**

By market value, Novartis is the larger: $300.5B against $254.5B for Thermo Fisher Scientific. By revenue in its latest fiscal year, Novartis is the larger: $54.5B against $44.6B for Thermo Fisher Scientific.

**Which has the higher P/E ratio?**

Thermo Fisher Scientific: 36.2, against 30.4 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Novartis: 32.4%, against 17.4% for Thermo Fisher Scientific. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Thermo Fisher Scientific: $39.4B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Novartis and Thermo Fisher Scientific?**

In their latest 13F filings, Ken Fisher, Primecap team, Larry Robbins, Andrew Spokes, Jeremy Grantham (co-founder) and Dodge & Cox team hold both.

### Cite this page

Funkfolio, “Novartis vs Thermo Fisher Scientific”, data as of 18 November 2026. https://funkfolio.com/compare/nvs-vs-tmo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
